Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

NCT07181161 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

177

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Prostate Cancer

Interventions

DRUG: AZD0516
DRUG: AZD9574

Sponsor

AstraZeneca

Collaborators

[object Object]